Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07498335 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial sites expanded: 9 → 12 locationsStart date changed from estimate of Aug 26, 2026 to Aug 6, 2026 · Eligibility criteria expanded, about 40 words · Secondary endpoints: details revised at 1 of 6 entries · 2 moreShow 5 more changesShow less
Start date changed from estimate of Aug 26, 2026 to Aug 6, 2026
Eligibility criteria expanded, about 40 words
Secondary endpoints: details revised at 1 of 6 entries
Study description revised
Publications: details revised at 1 of 1 entry
MinorTrial sites expanded: 6 → 9 locationsv7
NotableRecruitment openedTrial sites expanded: 2 → 6 locationsv6Show 1 more changeShow less
Trial sites expanded: 2 → 6 locations
MinorRe-verified, no change to tracked fieldsv5
MinorStudy sites: 0 to 2v4
NotablePrimary completion pushed from Nov 29, 2030 to Sep 15, 2031Completion pushed from Jan 31, 2031 to Dec 13, 2032 · Start date: Oct 2, 2026 to Aug 26, 2026v3Show 2 more changesShow less
Completion pushed from Jan 31, 2031 to Dec 13, 2032
Start date: Oct 2, 2026 to Aug 26, 2026
MinorPublications: details revised at 1 of 1 entryv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).